(R,S)-3-(2-碘-5-硝基苯甲酰)-1-(1-甲基-2-哌啶甲基)-1H-吲哚结构式
|
常用名 | (R,S)-3-(2-碘-5-硝基苯甲酰)-1-(1-甲基-2-哌啶甲基)-1H-吲哚 | 英文名 | AM1241 |
|---|---|---|---|---|
| CAS号 | 444912-48-5 | 分子量 | 503.33 | |
| 密度 | 1.3±0.1 g/cm3 | 沸点 | 630.7±55.0 °C at 760 mmHg | |
| 分子式 | C22H22IN3O3 | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | 335.2±31.5 °C | |
| 符号 |
GHS07, GHS08 |
信号词 | Danger |
用途AM1241 是一种有效的,典型的[2],选择性的 CB2 receptor 激动剂,对小鼠脾脏的 CB2 受体的 Ki 值为 3.4 nM,对大鼠大脑 CB1 受体的 Ki 值为 280 nM,在啮齿动物组织中,对 CB2 受体的选择性是对 CB1 受体的 280 倍[1]。 AM1241 能够缓解偏头痛、中风和神经性头痛,对帕金森病也有效果[2]。AM1241 可以抑制氧化损伤,通过 Akt 和 Erk1/2 的磷酸化激活 STAT3[3]。 |
| 中文名 | (2-碘-5-硝基苯基)(1-((1-甲基哌啶-2-基)甲基)-1H-吲哚-3-基)甲酮 |
|---|---|
| 英文名 | am-1241 |
| 英文别名 | 更多 |
| 描述 | AM1241 是一种有效的,典型的[2],选择性的 CB2 receptor 激动剂,对小鼠脾脏的 CB2 受体的 Ki 值为 3.4 nM,对大鼠大脑 CB1 受体的 Ki 值为 280 nM,在啮齿动物组织中,对 CB2 受体的选择性是对 CB1 受体的 280 倍[1]。 AM1241 能够缓解偏头痛、中风和神经性头痛,对帕金森病也有效果[2]。AM1241 可以抑制氧化损伤,通过 Akt 和 Erk1/2 的磷酸化激活 STAT3[3]。 |
|---|---|
| 相关类别 | |
| 靶点 |
Ki: 3.4 nM (Mouse spleen CB2 receptor), 280 nM (Rat brain CB1 receptor)[1] |
| 体外研究 | AM1241是一种有效的选择性CB2受体激动剂,在小鼠脾脏中Ki为3.4 nM,大鼠脑中CB1受体的Ki为280 nM,对啮齿动物组织中CB2受体的选择性为82倍[1]。 AM1241降低氧化应激水平,增强旁分泌生长因子的产生,降低TGF-β1和PDGF水平,通过Akt和Erk1/2的磷酸化激活Stat3 [3]。 |
| 体内研究 | AM1241(0.1-3mg/kg,ip)剂量依赖性地抑制大鼠的感觉超敏反应。在缺乏CB1受体的小鼠中,AM1241分别抑制1 mg/kg和3 mg/kg的触觉超敏反应和热敏感[1]。 AM1241(0.75,1.5,3,6,12 mg/kg,ip)减轻MPTP诱导的帕金森病并促进PD小鼠多巴胺能(DA)神经元的再生[2]。 |
| 参考文献 |
| 密度 | 1.3±0.1 g/cm3 |
|---|---|
| 沸点 | 630.7±55.0 °C at 760 mmHg |
| 分子式 | C22H22IN3O3 |
| 分子量 | 503.33 |
| 闪点 | 335.2±31.5 °C |
| PSA | 71.06000 |
| LogP | 3.41 |
| 外观性状 | yellow |
| 蒸汽压 | 0.0±1.8 mmHg at 25°C |
| 折射率 | 1.693 |
| 储存条件 | -20℃ |
| 水溶解性 | DMSO: ~18mg/mL at 60°C |
| 符号 |
GHS07, GHS08 |
|---|---|
| 信号词 | Danger |
| 危害声明 | H315-H319-H334-H335 |
| 警示性声明 | P261-P305 + P351 + P338-P342 + P311 |
| 个人防护装备 | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| 危害码 (欧洲) | Xn |
| 风险声明 (欧洲) | 36/37/38-42/43 |
| 安全声明 (欧洲) | 22-26-36/37-45 |
| 危险品运输编码 | NONH for all modes of transport |
|
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain.
Pain 152 , 1976-87, (2011) Drug self-administration methods were used to test the hypothesis that rats would self-medicate with a cannabinoid CB(2) agonist to attenuate a neuropathic pain state. Self-medication of the CB(2) ago... |
|
|
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS.
Proc. Natl. Acad. Sci. U. S. A. 100 , 10529-10533, (2003) We designed AM1241, a selective CB2 cannabinoid receptor agonist, and used it to test the hypothesis that CB2 receptor activation would reverse the sensory hypersensitivity observed in neuropathic pai... |
|
|
Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats.
Br. J. Pharmacol. 162 , 428-40, (2011) Cannabinoid CB₂ receptor activation by selective agonists has been shown to produce analgesic effects in preclinical models of inflammatory and neuropathic pain. However, mechanisms underlying CB₂-med... |
| (2-iodo-5-nitrophenyl){1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}methanone |
| Dacinostat |
| LAQ-824 |
| (2-Iodo-5-nitrophenyl){1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl}methanone |
| (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide |
| UNII-V10P524501 |
| (2-Iodo-5-nitrophenyl)(1-((1-methylpiperidin-2-yl)methyl)-1H-Indol-3-yl)methanone |
| 2-Propenamide, N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- |
| Methanone, (2-iodo-5-nitrophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]- |
| (R,S)-3-(2-Iodo-5-nitrobenzoyl)-1-(1-methyl-2-piperidinylmethyl)-1H-indole |
| (2E)-N-Hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide |
| (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide |
| NVP-LAQ824 |
| UNII:DLM851L3RD |
| S1095_Selleck |
| AM1241 |